BFRI biofrontera-us.com: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Biofrontera (BFRI)

Biofrontera Inc. has reached a stage of maturity by developing current keratosis therapy methods and expanding insurance limits. This price action on GURU.Markets with the 1.22 metric highlights the market power of a business that profits from high-margin exclusive skin treatment equipment. Stable demand for prescription drugs provides the assets with defensive qualities and ensures revenue resilience regardless of economic phases.

BFRI - biofrontera-us.com Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for Biofrontera, Inc. (BFRI)

- price and consensus price forecast:
Quote Chart Biofrontera Inc|BFRI - Analyst Consensus Forecast
- market capitalization data:
Market Value Biofrontera Inc.|BFRI - Enterprise Value
- book capitalization data:
Book Value per Share Biofrontera|BFRI - Company Book Value|Market Value to Book Value biofrontera-us.com|BFRI - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Biofrontera Inc.|BFRI - Long-Term Debt to Capital|Short-Term Debt to Capital Biofrontera Inc|BFRI - Company Total Debt|Debt to Net Assets Ratio Biofrontera Inc.
Initial company analysis:biofrontera-us.com
Core merchandise of Biofrontera, Inc.

The "razor-and-blade" model of Biofrontera Inc. (BFRI) ensures a steady cash flow through recurring gel sales. Analyzing the share of long-term loans in equity allows for an assessment of the sustainability of this scaling strategy. The current value of 1.22 reflects the ratio of liabilities with a maturity of over one year to the market value of assets. A decrease in this coefficient minimizes financial risks but may signal a slowdown in expansion. The asset is categorized as a high-risk biopharmaceutical security.

Direct competitors

Long-Term Liabilities to Equity Krystal Biotech Inc|Apogee Pharma (APGE) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Arcutis Corp (ARQT)|Long-Term Debt to Capital VCEL (Vericel Corporation)|orukatx.com - Long-Term Debt to Capital|Long-Term Debt to Equity Sanara (SMTI)|DBVT: Long-Term Debt to Capital Coefficient|SLSN (solesence.com) - Long-Term Debt to Equity|Journey Medical Corporation (DERM) - Long-Term Debt to Equity Ratio|FBRX (Forte Biosciences, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital empro.my (EMPG)|Sol-Gel Technologies Ltd. (SLGL) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient AXIL (reviveprocare.com)|Long-Term Debt to Equity MDCX|Verrica Pharmaceuticals Inc - Ratio of Long-Term Indebtedness to Capital|Hoth - Long-Term Debt to Equity|VYNE - Long-Term Debt to Capital|sonomapharma.com - Long-Term Debt to Capital|QNRX (Quoin Pharmaceuticals Ltd.) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Azitra Corp (AZTR)|Long-Term Debt to Capital Ratio Dermata Corp|Long-Term Debt to Capital Elevai Labs Inc. (ELAB)|Long-Term Debt to Equity revance.com (RVNC)